Condition

Recurrent B Acute Lymphoblastic Leukemia clinical trials and research

• 7Clinical trials
• 4Countries

Newest Recurrent B Acute Lymphoblastic Leukemia clinical trials

All recruiting trials (7)

• Pomalidomide after CAR T-cell therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma

  This phase 1 study tests whether pomalidomide, given after CD19 CAR T-cell therapy, is safe and may help people whose CD19+ B-cell leukemia or lymphoma has come back or not responded.

  Recruiting Phase 1 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07532525

• Erwinia asparaginase and venetoclax added to blinatumomab for relapsed/refractory CD19+ B‑ALL

  This will test whether adding recombinant Erwinia asparaginase and venetoclax to blinatumomab helps adolescents and adults (12–55) with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07133997

• CAR T cell therapy for children with acute lymphoblastic leukemia

  This study is testing a new type of CAR T cell therapy to see if it can safely help children and young adults with hard-to-treat leukemia.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT06777979

• Genetically engineered CAR T-cells for treating certain blood cancers

  This study is testing a new type of treatment using specially modified immune cells to see if they can help people with certain blood cancers that haven't responded to other treatments.

  Recruiting at 2 sites Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT05418088

• Blinatumomab versus blinatumomab plus nivolumab for first-relapse CD19+ B‑ALL

  This test sees if adding nivolumab to blinatumomab helps children and young adults (ages 1–30) with first-relapse CD19+ B‑cell acute lymphoblastic leukemia, including people with Down syndrome.

  Recruiting at 154 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 226 other locations · NCT04546399

• Inotuzumab ozogamicin and blinatumomab with optional ponatinib for CD22-positive B-cell acute lymphoblastic leukemia

  This trial will test whether inotuzumab ozogamicin followed by blinatumomab, with or without ponatinib, can help people with CD22-positive B-cell acute lymphoblastic leukemia who are newly diagnosed, have relapsed, or are refractory to prior therapy.

  Recruiting at 89 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 284 other locations · NCT03739814

• Using inotuzumab ozogamicin with chemotherapy to treat acute lymphoblastic leukemia

  This study is testing if a new drug combined with lighter chemotherapy can help older patients with acute lymphoblastic leukemia who can't handle stronger treatments.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT01371630

Related topics

Quick answers

How many Recurrent B Acute Lymphoblastic Leukemia clinical trials are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 4 countries. The most sites are in United States (7 trials), Puerto Rico (2 trials), Australia (1 trial), Canada (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 4, Phase 2: 2, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →